Earnings Call · Q1 FY2022·2022-05-10

Q1 22EPS -1.30%·Rev n/aQ4 21EPS -10.94%·Rev n/aQ3 21EPS -16.13%·Rev n/aQ2 21EPS -7.14%·Rev n/a⚠ consensus missing

Revolution Medicines, Inc. RVMD

David Errington — Investor Relations

Mark Goldsmith — Chairman and Chief Executive Officer

Jack Anders — Senior Vice President of Finance and Principal Financial Officer

−11.8%1d on move date−8.6% vs SPY3d−13.5%5d−7.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RVMD calls or request research access.

More RVMD calls Browse calls Request research access